The Effect of Osteopathic Manipulative Techniques on Human Tear Proteins

June 2, 2026 updated by: David Duriancik, Lake Erie College of Osteopathic Medicine
This is a pilot study to determine if osteopathic manipulation can alter the concentration of proteins in human tears.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • United States
    • Pennsylvania
      • Erie, Pennsylvania, United States, 16506
        • Plaza 38 Medical Offices
        • Contact:
        • Contact:
        • Principal Investigator:
          • David Duriancik, Ph.D.
        • Sub-Investigator:
          • Jonathan Sharp, B.S.
        • Sub-Investigator:
          • Jan Hendryx, D.O.
        • Sub-Investigator:
          • Stephany Esper, D.O.
        • Sub-Investigator:
          • Jacob Cukierski, D.O.
        • Sub-Investigator:
          • Ava Jones, B.S.
        • Sub-Investigator:
          • Benjamin DuValle, B.S.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Individuals older than 18 years of age at the time of enrollment
  • Individuals that understand the study procedures and provide voluntary, informed consent
  • Individuals willing and able to receive OMT

Exclusion Criteria:

  • Individuals younger than 18 years of age
  • Individuals who are pregnant or lactating
  • Individuals physically unable to receive OMT

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Sham Comparator: Sham
Other: Sham
Sham protocol including holding of the occiput and thoracic area and cranial vault hold without interaction with the motion.
Experimental: Osteopathic Manipulative Treatment
Sequential OMT of suboccipital 4-step release, occipital mastoid suture release, and sphenopalatine ganglion release.
Other: Osteopathic Manipulative Treatment
Sequential OMT of suboccipital 4-step release, occipital mastoid suture release, and sphenopalatine ganglion release.
Other Names:
  • OMT

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Total tear protein concentration
Time Frame: Baseline, 1 hour, and 1 week
Total protein concentration assessed using the BCA assay
Baseline, 1 hour, and 1 week
Secretory Immunoglobulin A
Time Frame: Baseline, 1 hour, and 1 week
Human IgA, also known as human immunoglobulin A, is an antibody that is produced by the immune system in response to antigens. It is the most abundant immunoglobulin in mucosal secretions, such as saliva, tears, and breast milk, and plays a key role in defense against pathogens at mucosal surfaces. IgA works by binding to specific antigens and preventing them from entering the body's tissues. It can also activate complement and promote phagocytosis by immune cells. This protein typically represents 5-15% of total protein in tears.
Baseline, 1 hour, and 1 week
Tumor necrosis factor - alpha (TNFa)
Time Frame: Baseline, 1 hour, and 1 week
TNF alpha is a multifunctional proinflammatory cytokine that belongs to the tumor necrosis factor (TNF) superfamily. This cytokine is mainly secreted by macrophage and bind to its receptors, TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. TNF alpha is involved in the regulation of immune cells, cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation.
Baseline, 1 hour, and 1 week
Lipocalin-1
Time Frame: Baseline, 1 hour, and 1 week
The protein encoded by this gene belongs to the lipocalin family. Lipocalins are a group of extracellular proteins that are able to bind lipophiles by enclosure within their structures to minimize solvent contact. This protein may bind hydrophobic ligands and inhibit cysteine proteinases. This protein is also known as Tear Prealbumin and typically represents 15-25% of total protein in tears.
Baseline, 1 hour, and 1 week
secreted Phospholipase A2 (type IIA)
Time Frame: Baseline, 1 hour, and 1 week
Phospholipases A2 (PLA2s) make up a superfamily of enzymes that hydrolyze the ester bond of phosphoglycerides at the sn-2 position to release free fatty acid and lysophospholipids. The sPLA2 responsible for the release of arachidonic acid in inflammation was believed to be Type IIA. Although recently discovered isoforms of PLA2 clearly contribute to the release of arachidonic acid, sPLA2 (Type IIA) continues to be a protein of interest in the field of inflammation.
Baseline, 1 hour, and 1 week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Lake Erie College of Osteopathic Medicine

Investigators

  • Principal Investigator: David Duriancik, Ph.D., Lake Erie College of Osteopathic Medicine

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

July 1, 2026

Primary Completion (Estimated)

August 1, 2026

Study Completion (Estimated)

October 1, 2026

Study Registration Dates

First Submitted

June 2, 2026

First Submitted That Met QC Criteria

June 2, 2026

First Posted (Actual)

June 8, 2026

Study Record Updates

Last Update Posted (Actual)

June 8, 2026

Last Update Submitted That Met QC Criteria

June 2, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 33-165

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on No Disease or Condition is Being Directly Studied

Clinical Trials on Osteopathic Manipulative Treatment

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe